Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 2;15(1):2165390. doi: 10.1080/19420862.2023.2165390

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work was authored as part of the Contributor’s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.

This is an Open Access article that has been identified as being free of known restrictions under copyright law, including all related and neighboring rights (https://creativecommons.org/publicdomain/mark/1.0/). You can copy, modify, distribute, and perform the work, even for commercial purposes, all without asking permission.

PMC Copyright notice

Figure 4. — Improved pharmacokinetics of CAP256.J3LS achieved by altering surface charge of J3. (a) In vivo half-life of CAP256- variants assessed in a human FcRn knock-in mouse model. (b) Sequence of J3 with Arg and Lys residues highlighted, and J3 paratope residues are underlined. (c) Accessible surface area of Arg and Lys residues. Residues above the dotted line were altered mutationally to reduce electropositivity. (d) Arg and Lys residues that were selected for mutations were shown in the structure of J3 in complex with gp120 (PDB ID: 7RI1). (e) Neutralization IC80 fold change, heparin chromatography retention volume, and autoreactivity of CAP256.J3LS variants. (f) In vivo half-life of CAP256.J3LS variants.